Novel Combination of Mesenchymal Stem Cell-Conditioned Medium with Sorafenib Have Synergistic Antitumor Effect of Hepatocellular Carcinoma Cells

OBJECTIVE: Hepatocellular carcinoma (HCC) is the most common liver malignancy. Sorafenib is the first-line systemic treatment for advanced HCCs. However, due to safety concerns, researchers are now looking for ways to boost the efficacy of the medication. One approach for reducing toxicity is combin...

Descripción completa

Detalles Bibliográficos
Autores principales: Seyhoun, Iman, Hajighasemlou, Saieh, Ai, Jafar, Hosseinzadeh, Faezeh, Mirmoghtadaei, Milad, Seyhoun, Seyed Moein, Parseh, Benyamin, Abdolahi, Shahrokh, Ghazvinian, Zeinab, Shadnoush, Mahdi, Verdi, Javad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485565/
https://www.ncbi.nlm.nih.gov/pubmed/30678447
http://dx.doi.org/10.31557/APJCP.2019.20.1.263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485565/
https://www.ncbi.nlm.nih.gov/pubmed/30678447
http://dx.doi.org/10.31557/APJCP.2019.20.1.263

Ejemplares similares